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OBJECTIVES: To disseminate transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) as an alternative
to investigate mediastinal tumoral lesions because it is an underused modality that has been available in Brazil for
more than 15 years.
METHODS: Descriptive analysis of a single endoscopy service’s experience since 1997 in the accomplishment of EUS-
FNA for mediastinal staging of previously known malignancies (Group 1) or diagnostic definition of suspect lymph
nodes and masses (Group 2).
RESULTS: EUS-FNA was performed in 51 patients between 26 and 87 years of age. The diameter of the lesions
ranged between 1.1 and 9.8 cm (mean 3.9 cm). Their location corresponded to the following stations: higher
paratracheal (4 cases), lower paratracheal (7), aortic window (12), para-aortic (6), subcarinal (9), paraesophageal (8),
and hilar (5). In Group 1, 17 patients had previously diagnosed primary lung (9), breast (4), kidney (2), colon (1), and
bladder (1) cancer. Fifteen of these punctures were positive for malignity. Two others were later submitted to
mediastinoscopy, which identified metastases not detected by EUS-FNA. Group 2 comprised 34 patients. Among
these patients, EUS-FNA diagnosed 22 neoplasms, five cases of tuberculosis and two duplication cysts. Cytology was
inconclusive or without a specific diagnosis in five other cases. Mediastinoscopy identified two undiagnosed cases of
oat-cell carcinoma, one lymphoma and one cryptococcosis, and confirmed one reactive lymphadenitis. There were
no complications related to the method.
CONCLUSIONS: EUS-FNA obviated the need for surgical procedures in 86.3% of cases. Therefore, oncologists,
pulmonologists, and thoracic surgeons should always remember the technique’s potential and availability.
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INTRODUCTION
The association between endoscopic techniques and
ultrasound first developed in the 1980s. The repercussions
and clinical impact of this minimally invasive technological
advance have been broadly highlighted in the international
scientific literature and more recently expanded to pulmo-
nology and thoracic oncology.
Endobronchial ultrasound (known as EBUS) has faced
greater technical bottlenecks, related to the smaller dia-
meters of the bronchoscope, its working channel, the
patients’ airways and, especially, the interface between the
ultrasound and air.1 The first sectorial echobronchoscope
was launched on the international market only in the
middle of the first decade of 2000.
Gastrointestinal endosonography (known as EUS), on the
other hand, has been in use as a routine procedure for more
than 15 years at large hospitals performing high-complexity
procedures, including those in Brazil.2-4 Its diagnostic and
therapeutic range has been well established for pancreatic
and pelvic diseases; mediastinal lesions can also be
approached through the intrathoracic esophagus.5,6 Fine-
needle aspiration (FNA) of masses and lymph nodes through
the esophageal wall has been performed at specialized
centers, with minimal risks of infection or bleeding and
without great technical difficulty.5-8 The importance and
usefulness of EUS for the mediastinal staging of primary lung
cancer has been well known since 1996.6 The main limitation
of EUS is its inability to access the anterior mediastinum
because of the interference of air present in the trachea.1,7,8
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This study aims to assess the performance of EUS-guided
FNA in diagnosing mediastinal tumor lesions (including
lymph node enlargements) and to describe some advan-
tages and particularities of the technique.
MATERIAL AND METHODS
This observational, retrospective, and cross-sectional
experience analysis reports the experience of a single
endosonography service linked to a private hospital in Sao
Paulo City between February 1997 and January 2011. All
clinical data (including copies of radiological and endoso-
nography images) were obtained from the service’s compu-
terized database.
The demands for EUS for mediastinal assessment
purposes were spontaneous because the patients’ own
physicians referred them due to pathological findings on
chest-Computerized tomography (CT) and, in some more
recent cases, on Positron emission tomography (PET) scans.
For the sake of this study, patients were classified into
two groups according to the purpose of the examination:
Group 1—EUS-FNA performed for mediastinal staging of
previously known malignant tumors; and Group 2—EUS-
FNA performed for diagnostic definition of lymph nodes or
suspected mediastinal masses. No technical or logistic
differences occurred when the procedure was accomplished
in both groups, which always followed the same service
routine.
All examinations took place in an outpatient setting,
under general anesthesia, starting with conventional upper
digestive endoscopy. Then echoendoscopy was used to
identify the mediastinal lesions previously detected on
radiology exams. Under a direct and real-time ultrasound
view, one single lesion (the largest in cases of multiple
identified lesions) was punctured with a dedicated 22-gauge
endoscopic needle. Once guided into the target lesion, the
needle was moved back and forth within the mass while
applying suction with a 20-ml syringe. At least three needle
punctures were made to obtain adequate tissue specimens.
Frozen-section examination was not performed during the
procedure in any of the cases. The aspirated material was
fixed in formaldehyde and analyzed through the cell-block
technique. In case of inconclusive cytopathology results, the
patient’s physician-in-charge was asked for further informa-
tion on clinical monitoring, other diagnostic methods, and
the respective final diagnosis in each case.
Approval for this study was obtained from the local
Institutional Review Board in compliance with the National
Health Council Resolution 196/96.
RESULTS
Out of 1,639 gastrointestinal endosonographies per-
formed during the study period, 51 (3.1%) looked for
mediastinal lesions. This series involved 37 (72.5%) men and
14 women between 26 and 87 years old (median 65 years).
Out of these 51 patients, 23 (45.1%) manifested thoracic
symptoms (dysphagia, dyspnea, thoracic pain), 22 (43.1%)
reported nonspecific signs and symptoms (fever and weight
loss), and 6 (11.8%) were asymptomatic.
The forwarding physicians included 22 (43.1%) oncolo-
gists, 18 (35.3%) clinical pulmonologists and thoracic
surgeons, and 11 (21.6%) others (general clinicians, digestive
surgeons, and cardiologists). It should be highlighted that
out of the 51 EUS performed for mediastinal assessment
purposes, 23 (45.1%) happened in the final four years of the
research period, and these cases were mostly referred by
pulmonologists and thoracic surgeons.
Endoscopic alterations (extrinsic compression) were
found in 24 (47.1%) patients, three of whom already
displayed esophageal stenosis.
In Group 1 (with previously known malignant disease,
forwarded for mediastinal staging), 17 patients were
included, 9 with primary lung tumors, 4 with breast tumors,
2 with kidney tumors, 1 with a colon tumor, and 1 with a
bladder tumor. Out of these 17 patients, a previous PET scan
had been done in only 4, all of whom were considered
‘‘positive’’ for the suspected mediastinal lesion. The
diameter of the punctured lesions ranged from 1.1 to
6.8 cm, with an average of 3.7 cm. Their location
(Mountain, 1997)9 corresponded to stations 2R (2 cases),
2L (1), 4R (1), 4L (2), #5 (1), #6 (1), #7 (3), #8 (2), 10R (1),
and 10L (3). EUS-FNA demonstrated metastatic involve-
ment in 15 out of 17 (88.2%) patients in Group 1. One case
was negative, and another was inconclusive—the respective
lymph node stations sampled by EUS were the paraeso-
phageal (#8) and the left hilar (10L). Both cases were later
submitted to classical cervical mediastinoscopy, which
identified metastases in lower paratracheal lymph nodes
(#4) that were previously undetected through EUS.
Group 2 (undiagnosed lymph node enlargements or
mediastinal masses) comprised 34 patients. The diameter
of the punctured lesions varied from 1.6 to 9.8 cm (average
4.0 cm). Their location (Mountain, 1997)9 corresponded to
stations 2L (one case), 4R (3), 4L (1), #5 (11), #6 (5), #7 (6),
#8 (6), and 10L (1). Among the 34 patients in Group 2, 22
(64.7%) ‘‘new’’ tumors were diagnosed through EUS-FNA,
including epidermoid carcinoma (10), adenocarcinoma (5),
oat-cell (3), lymphoma (2), sarcoma (1), and neuroendocrine
carcinoma (1). Other diagnoses established in this group
included tuberculosis (5) and duplication cyst (2). Cytology
was not malignant (but without a specific diagnosis) in three
cases and inconclusive in two others—these five patients
were later submitted to mediastinoscopy, which identified
two other cases of oat-cell carcinoma, one non-Hodgkin B-
cell lymphoma, and one ganglionic cryptococcosis, in
addition to confirming one case of non-specific reactive
lymphadenitis. Figure 1 displays a flow chart that sum-
marizes the procedures and diagnoses in this study.
Figure 2A illustrates a clinical case from Group 1;
Figure 2B illustrates a clinical case from Group 2.
There were no complications related to the method.
DISCUSSION
Despite its technical and commercial availability, EUS is
still rather underused in the treatment of thoracic illnesses.
Aside from its well-established importance for lung cancer
staging,6,10 its indication extends to other clinical situations,
such as mediastinal lymph node enlargement of unknown
causes or primary tumor masses and cystic lesions (for
diagnostic or symptom relief purposes).11
Considering each patient’s final diagnosis as the gold
standard, the general sensitivity of EUS-FNA in our study
was 88.0%, with 11.7% false negative cases. These rates still
apply if the sample is limited to the 17 cases in Group 1. In a
recent meta-analysis6 restricted to lung cancer cases, the
general EUS-FNA sensitivity was 84% for metastasis
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detection (N2 and/or N3), with a global false-negative rate
of 19%.
The only other Brazilian publication found that addressed
this issue12 assessed 25 EUS-FNA performed for the sake of
diagnostic clarification of mediastinal masses and lymph
nodes. Most (48%) lesions were neoplastic, while 24% were
inflammatory or infectious. Normal lymphatic tissue was
obtained in three cases (12%) and, in four others (16%),
insufficient material was sampled. No data are available on
other complementary methods used to define the diagnosis
for inconclusive cases.
The comparison between different methods (EUS, EBUS,
and surgical mediastinoscopy) in mediastinal staging for
primary lung cancer has been a recurrent and widely
discussed theme. This technical choice depends, among
other factors, on the patient’s clinical condition, the degree
of suspected mediastinal involvement, the location of the
primary tumor, the histological type, diameter and level of
the biopsied lymph nodes, the number of samples obtained
and, most importantly, the availability of different methods
at each institution, as well as the respective results the local
team has achieved.6,13
A larger number of recent EUS have been performed at
the request of chest physicians—we believe this change
resulted from these specialists’ recent contact with the large-
scale dissemination of EBUS in the international literature,
particularly regarding clinical repercussions. Both EUS and
EBUS are recommended by the main thoracic oncology
guidelines on the invasive mediastinal staging of primary
lung cancer.6,14,15
Yet other facts and peculiarities should be reminded:
- Any invasive sampling method is more specific than CT
scan and PET scan alone.16
- The association between EUS and EBUS in the same
patient reaches accuracy levels of more than 95%.17,18
These rates are quite encouraging, but combining both
sets of equipment, logistics, training, and the availability
of human and technical resources can hardly be justified
in commercial terms.
- Mediastinoscopy continues to be an obligatory comple-
mentary method whenever the above techniques reveal a
negative result.6,14,15 Some authors defend the position
that if the main goal is the diagnostic confirmation of
suspected metastatic disease detected through CT or PET
scan, then endosonography methods (EUS and/or
EBUS), if available, are an excellent alternative, with
high sensitivity and low morbidity levels. However, if
the main goal of invasive staging is to confirm the
absence of mediastinal involvement, in most cases,
surgical mediastinoscopy seems to be the best option.13
Based on Mountain’s former lymph node map9 (which
was the gold standard used during the study period), EUS
can assess and obtain samples from the upper and lower
paratracheal levels (stations #2 and #4), aortic window
(#5), subcarinal level (#7), paraesophageal level (#8),
inferior pulmonary ligament (#9), and pulmonary hilum
(#10). It should be noted that EUS also permits staging (and
biopsying) of primary pulmonary lesions when located near
(or eventually invading) the mediastinum.19 It has also been
capable of detecting (and biopsying) metastatic disease in
subdiaphragmatic lesions, such as those affecting the left
adrenal gland, celiac lymph nodes, and liver.6,8
The experience reported here includes a considerable
number (six cases) of samples obtained from the para-aortic
level (station #6), which deserves more careful and detailed
analysis. Strictly speaking, station #6 corresponds to the
lymph nodes anterior and lateral to the ascending aorta,
between a line tangent to the superior border and another to
the inferior border of the aortic arch.9 Hence, although
station#6 can indeed be visualized through EUS, it is rather
difficult to obtain samples through the esophageal route, as
that would imply transection of the pulmonary artery or the
aorta itself with the puncture needle. This location may
therefore have not been very precise under the EUS view, so
that some lymph nodes attributed to the para-aortic position
(if not all of them) may include lesions from stations 4L, #5
and even #8.
Because esophageal endosonography does not offer easy
anatomical reference points, the endoscopist’s experience
Figure 1 - Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) results and complementary mediastinoscopy performed in
51 patients.
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and knowledge of regional topography are fundamental for
a successful examination. Identifying and sampling lesions
located at the subcarinal level (#7), for example, will hardly
represent any difficulty because of its central position,
which is always anterior to the middle esophagus. It is
known that FNA of station #7 guided by endosonography
techniques (both EUS and EBUS) does not obtain better
results than a simple, ‘‘blind’’ transtracheal puncture.20 The
pulmonary hilar levels (#10), on the other hand, are
frequently mixed up with the inferior paratracheal stations
(#4), especially on the right. Such inadequate staging can
radically change therapeutic decisions—this means a pos-
sible N2 false-positive result. In lung cancer patients, if the
lymph nodes of stations 10 R/L (classified as N1) are
unintentionally interpreted as belonging to stations 4 R/L
(classified as N2), a malignant aspirate may exclude the
option for a radical surgical resection and the potential for
cure.8,13
There are further issues related to the routine adopted at
our service, which remains limited to the puncturing of a
single suspect lesion (the largest in case of multiple
identified lesions). Hence, it is recommended that, in all
cases, samples be obtained from at least two lymph node
zones as recently mapped by the International Association
for the Study of Lung Cancer (IALSC),21 always including
the subcarinal zone (station #7), to improve prognostic
definitions.
Equipment costs (especially disposable needles) and the
learning curve for use of the technique are highlighted as
the main difficulties that EBUS will still have to face be-
fore achieving greater availability and widespread use.1
International and Brazilian experiences with EUS-FNA, on
the other hand, have already demonstrated the method’s
ability to avoid surgical procedures (mediastinoscopy,
videothoracoscopy or even exploratory thoracotomy) in a
considerable number of patients—86.3% of cases in this
study.
CONCLUSION
EUS-FNA is an excellent alternative for mediastinal lesion
diagnosis and staging. Not only endoscopists but also
oncologists, pulmonologists, and thoracic surgeons should
consider its reliable potential and current availability.
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